Accueil   Diary - News   All news Roivant and Poxel Announce Strategic Agreement for Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide

Roivant and Poxel Announce Strategic Agreement for Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide

  • Poxel to receive upfront payment of $35 million (approximately €28 million), potential future development and regulatory milestone payments and salesbased payments of up to $600 million (approximately €486 million), and double-digit royalties on net sales
  • Roivant to concurrently invest $15 million (approximately €12 million) in Poxel through subscription to newly-issued ordinary shares at €8.5 per share
  • Poxel to contribute $25 million (approximately €20 million) to the development program
  • Roivant will be responsible for imeglimin’s development and commercialization in the U.S., Europe, and other countries outside of Poxel’s partnership with Sumitomo Dainippon Pharma

 

Roivant Sciences, a global healthcare company focused on realizing the full value of promising biomedical research, and POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders including type 2 diabetes, today announced the signing of a strategic development and license agreement for imeglimin, an investigational oral therapy which has been developed by Poxel for the potential treatment of type 2 diabetes, in the U.S., Europe, and all other countries not covered by Poxel’s existing agreement in East and Southeast Asia.1 

 

This partnership enables Roivant to add an innovative late-stage development program to its pipeline and Poxel gains a strategic development and licensing agreement for imeglimin beyond the company’s partnership with Sumitomo Dainippon Pharma.

 

 

Read the press release